Lithium's label names the everyday drugs that push its level up: water pills, NSAIDs, blood pressure drugs
The lithium label: "Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations." NSAIDs cut kidney blood flow, so lithium clears more slowly and the level rises.
Reasonable evidence with real limitations. how we score evidence
Caveat on this rating: The label lists NSAIDs and thiazides among the level-raising drugs; the Juurlink 2004 population study in this wave found neither independently associated with hospital admission for toxicity in older adults, while loop diuretics and ACE inhibitors were. Both are on this page.
Lithium has a narrow window between the level that works and the level that poisons, and the label says the window can be crossed by an ibuprofen or a blood pressure tablet.
Significant findings
Lithium carbonate prescribing information (Hikma, September 2026), boxed warning: "Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations. Facilities for prompt and accurate serum lithium determinations should be available before initiating treatment".
Drug Interactions summary: "Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. Recommend frequent monitoring of serum lithium concentration and adjust dosage when necessary." The mechanisms, from Table 4: diuretics because "Diuretic-induced sodium loss may reduce lithium clearance and increase serum lithium concentrations"; NSAIDs because they "decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations." For both, the intervention is "More frequent serum lithium concentration monitoring. Reduce lithium dosage based on serum lithium concentration and clinical response".
Two psychiatric interactions on the same list: "Serotonergic Agents: Increased risk of serotonin syndrome when co-administered with lithium." And: "Antipsychotics: There have been reports of neurologic adverse reactions in patients treated with lithium and an antipsychotic, ranging from extrapyramidal symptoms to neuroleptic malignant syndrome."
Worth asking
The drugs on this list are the ones people buy without asking: ibuprofen and naproxen for a headache, a water pill or an ACE inhibitor started by a cardiologist who may not know about the lithium. If you take lithium, the question is what painkiller is safe for you, and whether a lithium level is due after any new prescription. The Juurlink 2004 row in this wave measured which of these actually sent older patients to hospital.
Source
Lithium carbonate tablets and capsules: FDA-approved prescribing information, Boxed Warning and Drug Interactions 7.1 — Hikma Pharmaceuticals USA Inc.; US Food and Drug Administration (2026)
Regulator or national health body
How this was scored
- Study design
- Regulatory safety determination
- Funding
- Industry funded
- Published in
- Regulator or national health body
- Sample size
- not recorded
- Preregistered
- not recorded
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published September 21, 2026.
Questions
How strong is the evidence behind this?
veisund rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 57 out of 100 on our published rubric. One caveat travels with that badge: The label lists NSAIDs and thiazides among the level-raising drugs; the Juurlink 2004 population study in this wave found neither independently associated with hospital admission for toxicity in older adults, while loop diuretics and ACE inhibitors were. Both are on this page. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Lithium carbonate tablets and capsules: FDA-approved prescribing information, Boxed Warning and Drug Interactions 7.1 — Hikma Pharmaceuticals USA Inc.; US Food and Drug Administration (2026). Published in: Regulator or national health body. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Regulatory safety determination. Funding: Industry funded. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.